enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) (Padcev/Keytruda): FDA status

Approved Approved Dec 15, 2023. Indication: First line treatment of locally advanced or metastatic urothelial cancer. Company: Merck/Astellas/Seagen.

Regulatory history

• Dec 15, 2023: Approved. FDA approved pembrolizumab in combination with enfortumab vedotin ejfv for adults with locally advanced or metastatic urothelial cancer. renalandurologynews.com

All products in the FDA Tracker